Design and rationale of the CLEAR SYNERGY (OASIS 9) trial: A 2x2 factorial randomized controlled trial of colchicine versus placebo and spironolactone vs placebo in patients with myocardial infarction-Reference-Cited by-同舟云学术

Design and rationale of the CLEAR SYNERGY (OASIS 9) trial: A 2x2 factorial randomized controlled trial of colchicine versus placebo and spironolactone vs placebo in patients with myocardial infarction

Published:2024-09 Issue: Volume:275 Page:173-182
ISSN:0002-8703
Container-title:American Heart Journal
language:en
Short-container-title:American Heart Journal

Author:

d'Entremont Marc-André,Lee Shun Fu,Mian Rajibul,Kedev Sasko,Montalescot Gilles,Cornel Jan Hein,Stankovic Goran,Moreno Raul,Storey Robert F.,Henry Timothy D.,Skuriat Elizabeth,Tyrwhitt Jessica,Mehta Shamir R.,Devereaux P.J.,Eikelboom John,Cairns John A.,Pitt Bertram,Jolly Sanjit S.

Funder

Boston Scientific Corporation

Population Health Research Institute

Canadian Institutes of Health Research

Publisher

Elsevier BV

Reference34 articles.

1. 2022 AHA/ACC/HFSA Guideline for the management of heart failure;Heidenreich Paul;J Am Col Cardiol,2022

2. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association/American College of Cardiology Joint Committee on clinical practice guidelines;Virani;Circulation,2023

3. Efficacy and safety of low-dose colchicine after myocardial infarction;Tardif;New Engl J Med,2019

4. Heart failure after myocardial infarction: incidence and predictors;Jenča;ESC Heart Fail,2021

5. Inflammation, immunity, and infection in atherothrombosis;Libby;J Am Col Cardiol,2018

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients Following Acute Coronary Syndromes: From Lipid Lowering and Plaque Stabilization to Improved Outcomes;Journal of Clinical Medicine;2024-08-25